Landscape of Genomic Profiling and Circulating Tumor DNA Among Rare Genitourinary Cancers

Abstract

• •
  Current surveillance and treatment strategies of rare genitourinary cancers are heterogenous and often rely on classical imaging alone leaving opportunity for enhanced surveillance and treatment direction strategies.
• •
  Molecular residual disease assessment may offer many benefits to standard modalities including antecedent prediction of recurrence or progression compared to conventional surveillance, early and appropriate identification of patients appropriate for adjuvant treatment, potential for monitoring of treatment response, and adjudication of indeterminate imaging findings.
• •
  Comprehensive genomic profiling delineates tumor biology and actionable mutations for personalized medicine in this challenging to treat population including nonclassical targeted agents.